Following is information about the current pending grants.
R21 (Wang) -
"Group 1 CD1-restricted Autoreactive T cells in Inflammatory Disease"
The objective of this proposal is to evaluate the potential role of group 1 CD1-restricted autoreactive T cells, a novel subset of self-lipid antigen-specific T cells, in hyperlipidemia-induced chronic inflammatory diseases.
R01 (Meade) -
"Inhibition of Cancer-Associated Transcription Factors with Cobalt(III) Schiff Base Complexes"
Transcription factors are key mediators of disease processes including metastasis and tumor growth. The proposed research seeks to block these processes through the targeted and potent inhibition of cancer-associated transcription factors with conjugates containing transition metal complexes tethered to protein-specific oligonucleotides. The success of this research project will generate new chemical tools for understanding transcription factors in cancer biology with promise as chemotherapeutic agents with unique mechanisms of action.
R01 (Troyanovsky) -
"Actin filaments and cadherin clusters"
Our preliminary studies show that actin filaments continuously generate transient and highly adhesive cadherin clusters on the cell surface. The goal of our proposal is to study how epithelial cells including keratinocytes use these adhesive devices for different morphogenetic processes. Completing this goal will allow us to design animal experiments and clinical studies aimed at understanding the role of cadherin adhesion in wound healing and pathological morphogenesis, such as lymphocyte epidermal infiltration. The study is also a critical step toward the development of synthetic adhesion modulators and their application in medicine.
R01-Pending (Getsios) -
"Eph/Ephrin-mediated cell-cell communication in epidermal homeostasis and disease"
The major goal of this project is to understand how Eph receptor tyrosine kinases and their ephrin ligands mediate epidermal cell-cell communication to maintain tissue homeostasis. The project is focused on determining how keratinocytes switch from EphA2 to EphA1-dependent signaling pathways that promote differentiation in order to gain insight into restoring this receptor tyrosine kinase balance in inflammatory skin conditions, such as psoriasis.
1R01 CA180612-01 (Budunova) -
"Novel GR-targeted therapy for mantle cell lymphoma"
Current application status: Awarded The goals of this proposal are to evaluate anti-lymphoma activity of novel non-steroidal ligand of the glucocorticoid receptor, Compound A in vivo using novel mantle cell lymphoma mouse model, and xenograft models of MCL, as a single agent and combined with ubiquitin-proteasome degradation system inhibitors (UPSI). We also proposed to uncover mechanisms underlying cooperation between UPSI and Compound A. Application Status: Pending
1R01GM112945-01 (Budunova) -
"Integrative informatics approach to develop safe glucocorticoid therapies"
The ultimate goal of this proposal is to use integrative bioinformatics approach to develop novel safe (with fewer side effects) anti-inflammatory therapies targeting the glucocorticoid receptor (GR) for the patients suffering from dermatological diseases. In this application, we propose an integrative informatics approach to analyze complex molecular networks induced by glucocorticoids in skin, to identify druggable targets (atrophogenes) and established compounds (anti-atrophogenes) that could work in co-administration with glucocorticoids to ameliorate the skin atrophy while preserving anti-inflammatory potential of glucocorticoids. Current application status: Pending
Subaward (Paller) -
NIH (Prime: Yale)
"Consortium for Clinical Research in Inherited and Disorders of Keratinization"
Application Status: Pending
Complete and submit our grants form if your pending or funded grant uses a SDRC Core facility.